Adaptive and flexible clinical trials

Adaptive and Flexible Clinical Trials

Volumn , Issue , 2016, Pages 1-173

  Chin, Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85051690614     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (70)

1. Chin, R., Lee, B.Y. Principles and Practice of Clinical Trial Medicine, Elsevier, St. Louis, 2008.
2. Committee for Medicinal Products for Human Use. Reflection Paper on Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plan, Draft. 2006. Accessed 15 July 2010.
3. EMA. Report on the EMEA-EFPIA Workshop on Adaptive Designs in Confirmatory Clinical Trials. http://www.ema.europa.eu/pdfs/conferenceflyers/report_adaptivedesigns.pdf. Accessed 15 July 2010.
4. FDA. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. 2010.
5. FDA. Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071072.htm. Accessed 5 July 2010.
6. Sheiner, L.B. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997; 61:275-291.
7. Temple, B. Presentation at the Adaptive Designs Workshop, 2006.
8. Lehmann, E. L. 1993. Neyman-Pearson. Theories of Testing Hypothesis. J Am. Stat. Assc. 88:1242-1249.
9. Motulsky, H. 1995. Intuitive Statistics. Oxford University Press.
10. Bauer, P. and Köhne, K. 1994. Evaluation of experiments with adaptive interim analyses. Biometrics, 50:1029-1041.
11. Burman, C.-F. and Sonesson, C. 2006. Are flexible designs sound? [With discussion]. Biometrics, 62:664-683.
12. Chin, R., Lee, B.Y. 2008. Principles and Practice of Clinical Trial Medicine. Elsevier,. St. Louis.
13. Cui, L., Hung, H. M. J. and Wang, S. J. 1999. Modification of sample size in group sequential clinical trials. Biometrics. 55: 853: 857.
14. DeMets, D.L. and Lan, K.K. 1994. Interim analysis: The alpha spending function approach. Statistics in Medicine, 13:1341-1352.
15. Fisher, R. A. 1925. Statistical methods of research workers. Oliver and Boyd. Edinburgh.
16. Fisher, L.D. 1998. Self-designing clinical trials. Statistics in Medicine. 17: 1551:1562.
17. Food and Drug Administration. Guidance for Industry. 2010. Adaptive Design Clinical Trials for Drugs and Biologics.
18. Hartung, J. and Knapp, G. 2003. A new class of completely self-designing clinical trials. Biometrical Journal, 45:3-19.
19. Lehmann, E.L. 1993. Neyman-Pearson. Theories of Testing Hypothesis. J. Am. Stat. Assc. 88: 1242-1249.
20. Muller, H. H. and Schafer, H. 2001. Adaptive group sequential designs for clinical trials. Biometrics. 57: 886-891.
21. Proschan, M.A. and Hunsberger, S.A. 1995. Designed extension of studies based on conditional power. Biometrics, 51:1315-1324.
22. Tsiatis, A.A. and Mehta, C. 2003. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika, 90:367-378.
23. Wald, A. 1945. Sequential Tests of Statistical Hypothesis. Am Math. Stat. 16:117-186.
24. CAST Investigators. 1989. Preliminary report. NEJM. 321:406-412.
25. Chin, R. and Lee, B.Y. 2008. Principles and Practice of Clinical Trial Medicine. Elsevier: St. Louis, MO.
26. Chin, R. and Lee, B.Y. 2008. Principles and Practice of clinical trial medicine. Elsevier: St. Louis, MO.
27. Efron, B. 1971. Forcing a sequential experiment to be balanced. Biometrika. 58: 403-417.
28. Wei, L. J. and Lachin, J. M. 1988. Properties of the Urn Randomization in Clinical Trials. Cont. Clin. Trials. 9: 345-364.
29. Bauer, P. and Kohne, K. 1994. Evaluation of experiments with adaptive interim analyses. Biometrics. 50: 1029-1041.
30. Fisher, L.D. 1998. Self-designing clinical trials. Statistics in Medicine, 17:1551-1562.
31. Lan, K.K.G. and DeMets, D.L. 1983. Discrete sequential boundaries for clinical trials. Biometrika, 70:659-663.
32. Mehta, C.R. and Tsiatis, A.A. 2001. Flexible sample size considerations using information-based interim monitoring. Drug Information Journal, 35:1095-1112.
33. Proschan, M. A. and Hunsberger, S.A. 1995. Designed extension of studies based on conditional power. Biometrics. 51: 1315-1324.
34. Schmitz, N. 1993. Optimal Sequentially Planned Decision Procedures. Lecture Notes in Statistics, 79.
35. Chin, R. and Lee, B.Y. 2008. Principles and Practice of Clinical Trial Medicine. Elsevier. St. Louis, MO.
36. Anbar, D. 1984. Stochastic approximation methods and their use in bioassay and Phase I clinical trials. Communications in Statistics - Theory and Methods, 13:2451-2467.
37. Babb, J., Rogatko, A., and Zacks, S. 1998. Cancer Phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine, 17:1103-1130.
38. Braun, T.M. 2005. Generalizing the TITE-CRM to adapt for early- and late-onset toxicities. Statistics in Medicine, 25:2071-2083.
39. Cheung, Y. and Chappell, R. 2000. Sequential designs for Phase I clinical trials with late-onset toxicities. Biometrics, 56:1177-1182.
40. Chin, R. and Lee, B.Y. 2008. Principles and Practice of Clinical Trial Medicine. Elsevier. St. Louis, MO.
41. Dragalin, V., Fedorov, V., and Wu, Y. 2008. Adaptive designs for selecting drug combinations based on efficacy-toxicity response. Journal of Statistical Planning and Inference, 138(2):352-373.
42. Ivanova, A., Flournoy, N., and Chung, Y. 2007. Cumulative cohort design for dose finding. Journal of Statistical Planning and Inference, 137:2316-2327.
43. Ji, Y., Li, Y., and Bekele, N. 2007. Dose-finding in Phase I clinical trials based on toxicity probability intervals. Clinical Trials, 4:235-244.
44. O'Quigley, J. and Chevret, S. 1991. Methods for dose finding studies in cancer clinical trials: A review and results of a Monte Carlo study. Statistics in Medicine, 10:1647 -1664.
45. O'Quigley, J.O., Pepe, M., and Fisher, L. 1990. Continual reassessment method: A practical design for Phase I clinical trials in cancer. Biometrics, 46:33-48.
46. Orloff, J. 2009. The future of drug development: Advancing clinical trial design. Nature Reviews Drug Discovery, 8:949-957.
47. Thall, P.F. and Cook, J.D. 2004. Dose-finding based on efficacy-toxicity trade-offs. Biometrics, 60:684-693.
48. Whitehead, J., Zhou, Y., Stevens, J., and Blakey, G. 2004. An evaluation of a Bayesian method of dose escalation based on bivariate binary responses. Journal of Biopharmaceutical Statistics, 14:969-983.
49. Wijesinha, M.C. and Piantadosi, S. 1995. Dose-response models with covariates. Biometrics, 51:977-987
50. Brannath, W., Bauer, P., Maurer, W., and Posch, M. 2003. Sequential tests for non-inferiority and superiority. Biometrics, 59:106-114.
51. Chin, R. and Lee, B.Y. 2008. Principles and Practice of Clinical Trial Medicine. Elsevier. St. Louis, MO.
52. Hommel, G. and Kropf, S. 2001. Clinical trials with an adaptive choice of hypotheses. Drug Information Journal, 35:1423-1429.
53. Kropf, S., Hommel, G., Schmidt, U., Brickwedel, J., and Jepsen, M.S. 2000. Multiple comparison of treatments with stable multivariate tests in a two-stage adaptive design, including a test for non-inferiority. Biometrical Journal, 42:951-965.
54. Wang, S.J., Hung, H.M.J., Tsong, Y., and Cui, L. 2001. Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. Statistics in Medicine, 20:1903-1912.
55. Bauer, P. and Kohne, K. 1994. Evaluation of experiments with adaptive interim analyses. Biometrics, 50:1029-1041. (correction Biometrics, 52:380, 1996.)
56. Chi, G.Y.H. and Liu, Q. 1999. The attractiveness of the concept of a prospectively designed two-stage clinical trial. Journal of Biopharmaceutical Statistics, 9:537-547.
57. Cui, L., Hung, H.M.J., and Wang, S.-J. 1999. Modification of sample size in group sequential clinical trials. Biometrics, 55:853-857.
58. Denne, J.S. 2000. Estimation following extension of a study on the basis of conditional power. Journal of Biopharmaceutical Statistics, 10:131-144.
59. Hommel, G. 2001. Adaptive modifications of hypotheses after an interim analysis. Biometrical Journal, 43:581-589.
60. Lan, K.K.G. and Trost, D.C. 1997. Estimation of parameters and sample size reestimation. Proceedings of Biopharmaceutical Section, 48-51.
61. Lang, T., Auterith, A., and Bauer, P. 2000. Trend tests with adaptive scoring. Biometrical Journal, 42:1007-1020.
62. Lawrence, J. 2002. Design of clinical trials using an adaptive test statistics. Pharmaceutical Statistics, 1:97-106.
63. Lehmacher, W. and Wassmer, G. 1999. Adaptive sample size calculation in group sequential trials. Biometrics, 55:1286-1290.
64. Muller, H.-H. and Schafer, H. 2001. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and of classical group sequential procedures. Biometrics, 57:886-891.
65. Neuhäuser, M. 2001. An adaptive location-scale test. Biometrical Journal, 43:809-819.
66. Shen, Y. and Fisher, L. 1999. Statistical inference for self-designing designing clinical trials with a one-sided hypothesis. Biometrics, 55:190-197.
67. Wang, S.-J., Hung, H.M.J., Tsong, Y., and Cui, L. 2001. Group sequential test strategies for superiority and non-inferiority hypotheses in active controlled clinical trials. Statistics in Medicine, 20:1903-1912.
68. Wang, S.J. and Hung, H.M.J. 2005. Adaptive covariate adjustment in clinical trials. Journal of Biopharmaceutical Statistics, 15:605-612.
69. Food and Drug Administration. 2010. Guidance for Industry: Adaptive Design in Clinical Trials for Drugs and Biologics.
70. Chin, R. and Lee, B.Y. 2008. Principles and Practice of Clinical Trial Medicine. Elsevier: St. Louis, MO.